Compare Stocks: APGE, BIIB, ALNY, and ROIV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$218.98 -0.6%	$284.89	$197.81 ▼ $495.55	$29.48B	0.3	2.29 million shs	3.11 million shs
APGE Apogee Therapeutics	$134.19 +0.1%	$116.03	$34.34 ▼ $134.46	$8.30B	0.34	1.16 million shs	2.38 million shs
BIIB Biogen	$208.45 +3.3%	$201.70	$127.00 ▼ $219.72	$29.82B	0.17	1.46 million shs	1.21 million shs
ROIV Roivant Sciences	$34.59 +3.8%	$32.80	$10.90 ▼ $37.00	$23.97B	1.12	4.65 million shs	5.88 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+7.21%	-20.86%	-29.56%	-26.83%	-45.16%
APGE Apogee Therapeutics	+0.01%	-0.13%	+0.90%	+61.02%	+255.26%
BIIB Biogen	-0.56%	+0.84%	-6.62%	+6.71%	+52.95%
ROIV Roivant Sciences	-1.74%	-4.03%	-5.15%	+17.66%	+194.61%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$218.98 -0.6%	$284.89	$197.81 ▼ $495.55	$29.48B	0.3	2.29 million shs	3.11 million shs
APGE Apogee Therapeutics	$134.19 +0.1%	$116.03	$34.34 ▼ $134.46	$8.30B	0.34	1.16 million shs	2.38 million shs
BIIB Biogen	$208.45 +3.3%	$201.70	$127.00 ▼ $219.72	$29.82B	0.17	1.46 million shs	1.21 million shs
ROIV Roivant Sciences	$34.59 +3.8%	$32.80	$10.90 ▼ $37.00	$23.97B	1.12	4.65 million shs	5.88 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+7.21%	-20.86%	-29.56%	-26.83%	-45.16%
APGE Apogee Therapeutics	+0.01%	-0.13%	+0.90%	+61.02%	+255.26%
BIIB Biogen	-0.56%	+0.84%	-6.62%	+6.71%	+52.95%
ROIV Roivant Sciences	-1.74%	-4.03%	-5.15%	+17.66%	+194.61%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.92	Moderate Buy	$396.72	81.17% Upside
APGE Apogee Therapeutics	2.24	Hold	$121.25	-9.64% Downside
BIIB Biogen	2.56	Moderate Buy	$224.61	7.75% Upside
ROIV Roivant Sciences	2.75	Moderate Buy	$33.59	-2.89% Downside

Current Analyst Ratings Breakdown

Latest APGE, BIIB, ALNY, and ROIV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/4/2026	ALNY Alnylam Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$410.00 ➝ $315.00
8/4/2026	BIIB Biogen	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$221.00 ➝ $241.00
8/3/2026	BIIB Biogen	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$200.00 ➝ $215.00
8/3/2026	ALNY Alnylam Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$380.00 ➝ $340.00
8/3/2026	ALNY Alnylam Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform ➝ Strong-Buy	$420.00
8/3/2026	ALNY Alnylam Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$527.00 ➝ $450.00
7/31/2026	ALNY Alnylam Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
7/31/2026	ALNY Alnylam Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$485.00 ➝ $455.00
7/31/2026	ROIV Roivant Sciences	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/31/2026	ALNY Alnylam Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$445.00 ➝ $350.00
7/31/2026	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$400.00 ➝ $375.00

(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	7.89	$2.98 per share	73.50	$5.97 per share	36.68
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$13.23 per share	N/A
BIIB Biogen	$10.03B	3.07	$23.24 per share	8.97	$124.45 per share	1.67
ROIV Roivant Sciences	$8.26M	3,012.05	N/A	N/A	$7.35 per share	4.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	40.70	21.90	N/A	15.26%	104.81%	14.71%	N/A
APGE Apogee Therapeutics	-$255.84M	-$4.33	N/A	N/A	N/A	N/A	-32.64%	-31.25%	8/10/2026 (Estimated)
BIIB Biogen	$1.29B	$5.65	36.89	12.65	6.20	8.32%	11.18%	6.88%	N/A
ROIV Roivant Sciences	-$299.77M	-$0.60	N/A	N/A	N/A	-3,629.19%	-20.54%	-19.43%	8/6/2026 (Estimated)

Latest APGE, BIIB, ALNY, and ROIV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	APGE Apogee Therapeutics	-$1.07	N/A	N/A	N/A	$10.00 million	N/A
8/6/2026	Q1 2027	ROIV Roivant Sciences	-$0.2881	N/A	N/A	N/A	$2.00 million	N/A
7/29/2026	Q2 2026	BIIB Biogen	$2.94	$3.60	+$0.66	$0.66	$2.46 billion	$2.74 billion
5/11/2026	Q1 2026	APGE Apogee Therapeutics	-$1.0658	-$1.06	+$0.0058	-$1.06	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.94	3.13	3.06
APGE Apogee Therapeutics	N/A	32.59	32.59
BIIB Biogen	0.39	1.87	1.26
ROIV Roivant Sciences	N/A	18.37	18.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
APGE Apogee Therapeutics	79.04%
BIIB Biogen	87.93%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
APGE Apogee Therapeutics	24.30%
BIIB Biogen	0.25%
ROIV Roivant Sciences	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
APGE Apogee Therapeutics	91	61.88 million	46.84 million	Optionable
BIIB Biogen	7,500	147.75 million	147.39 million	Optionable
ROIV Roivant Sciences	860	719.27 million	655.97 million	Optionable

APGE, BIIB, ALNY, and ROIV Headlines

Recent News About These Companies

Edgestream Partners L.P. Takes Position in Roivant Sciences Ltd. $ROIV

August 4 at 3:51 AM | marketbeat.com

Roivant Sciences Ltd. $ROIV Shares Purchased by California State Teachers Retirement System

August 4 at 3:36 AM | marketbeat.com

Arrowstreet Capital Limited Partnership Grows Position in Roivant Sciences Ltd. $ROIV

August 4 at 3:12 AM | marketbeat.com

Hsbc Holdings PLC Sells 31,577 Shares of Roivant Sciences Ltd. $ROIV

August 3 at 4:31 AM | marketbeat.com

Amundi Has $41.02 Million Stake in Roivant Sciences Ltd. $ROIV

August 3 at 3:04 AM | marketbeat.com

Seven Fleet Capital Management LP Purchases New Shares in Roivant Sciences Ltd. $ROIV

August 2 at 6:31 AM | marketbeat.com

Roivant Sciences Ltd. $ROIV Position Raised by Perceptive Advisors LLC

August 2 at 6:07 AM | marketbeat.com

The Manufacturers Life Insurance Company Has $19.37 Million Stake in Roivant Sciences Ltd. $ROIV

August 2 at 5:27 AM | marketbeat.com

Janus Henderson Group PLC Purchases 177,339 Shares of Roivant Sciences Ltd. $ROIV

August 1 at 6:08 AM | marketbeat.com

Empowered Funds LLC Grows Stake in Roivant Sciences Ltd. $ROIV

August 1 at 4:24 AM | marketbeat.com

First Trust Advisors LP Purchases 195,101 Shares of Roivant Sciences Ltd. $ROIV

July 31, 2026 | marketbeat.com

Roivant Sciences (ROIV) Expected to Post Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

Roivant Sciences Ltd. $ROIV Shares Sold by Stempoint Capital LP

July 30, 2026 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares

July 30, 2026 | insidertrades.com

Eric Venker Sells 200,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

July 29, 2026 | marketbeat.com

Roivant Sciences Ltd. $ROIV Holdings Lessened by SB Investment Advisers UK Ltd.

July 29, 2026 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of "Moderate Buy" from Analysts

July 29, 2026 | americanbankingnews.com

Roivant Sciences Ltd. $ROIV is ADAR1 Capital Management LLC's 3rd Largest Position

July 29, 2026 | marketbeat.com

Roivant Sciences Ltd. $ROIV Shares Sold by Rubric Capital Management LP

July 28, 2026 | marketbeat.com

Maverick Capital Ltd. Takes $45.07 Million Position in Roivant Sciences Ltd. $ROIV

July 28, 2026 | marketbeat.com

Roivant Sciences (ROIV) Receives a Buy from Piper Sandler

July 26, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

APGE, BIIB, ALNY, and ROIV Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$218.98 -1.35 (-0.61%)

Closing price 03:59 PM Eastern

Extended Trading

$220.85 +1.87 (+0.85%)

As of 07:47 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Apogee Therapeutics NASDAQ:APGE

$134.19 +0.08 (+0.06%)

Closing price 04:00 PM Eastern

Extended Trading

$134.16 -0.03 (-0.02%)

As of 07:34 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Biogen NASDAQ:BIIB

$208.45 +6.63 (+3.29%)

Closing price 04:00 PM Eastern

Extended Trading

$208.00 -0.45 (-0.22%)

As of 07:43 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Roivant Sciences NASDAQ:ROIV

$34.59 +1.27 (+3.81%)

Closing price 04:00 PM Eastern

Extended Trading

$34.22 -0.37 (-1.08%)

As of 07:47 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APGE, BIIB, ALNY, and ROIV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APGE, BIIB, ALNY, and ROIV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APGE, BIIB, ALNY, and ROIV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

APGE, BIIB, ALNY, and ROIV Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Apogee Therapeutics NASDAQ:APGE

Biogen NASDAQ:BIIB

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APGE, BIIB, ALNY, and ROIV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APGE, BIIB, ALNY, and ROIV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APGE, BIIB, ALNY, and ROIV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

APGE, BIIB, ALNY, and ROIV Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Apogee Therapeutics NASDAQ:APGE

Biogen NASDAQ:BIIB

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools